FDA Approves Moderna’s mRNA Flu Vaccine for Older Adults
The FDA approved Moderna’s first mRNA flu vaccine, a step toward faster targeting of prevalent or virulent flu strains. After earlier refusing to review the application, the agency reversed course following public outcry. The vaccine is authorized for ages 50–64 and uses accelerated approval for 65+. Moderna expects readiness for the 2026–27 respiratory season.